Cronn Disease is a chronic, regenerative, inflammatory intestinal disease, which can weigh on any part of the gastrointestinal tract. For those with medium-weight Crohn, a combination of multiple factors is needed to develop a precise and effective treatment programme to achieve the objectives of abating symptoms, promoting mucous healing, preventing relapse and improving the quality of life.
I. Drug treatment: multipronged, precise interventions
1. Biological agents: The critical drug for the treatment of the moderately severe Crohn disease is the tumour cause of death – the α (TNF-α) constrictor. Inflisi alone is resistant to the specific combination of TNF-α, blocking its inflammation signal transmission, rapidly mitigating intestinal inflammation, effectively inducing decomposition and promoting mucous membrane healing. The same can be said for the Adam single resistance, etc., where it is easy to use and patients can inject themselves under the skin. In the use of biological agents, the risk of infection, particularly in the nodule branch bacterium, and the immunogenic properties of the drug need to be closely monitored.
2. Immunosuppressants: immunosuppressants such as sulfur and thiram are often used in conjunction with biological agents or as monopharmaceuticals. They reduce intestinal inflammation activity by inhibiting hysteria synthesis and regulating the immune function of the organism. However, indicators such as blood protocol, liver function are regularly monitored during use to prevent adverse effects such as bone marrow inhibition and liver toxicity.
3. Sugar cortex hormones: Sugar cortex hormones, such as pennisons and capponylons, may be applied for short periods of time during the period of acute onset of the disease when the biological agents are not yet working or the patient cannot withstand them. They can rapidly contain inflammation and alleviate symptoms such as abdominal pain and diarrhoea. However, the long-term use of sugar cortex hormones can cause a number of adverse effects, such as osteoporosis, hypertension, diabetes, etc., and should therefore be reduced or discontinued as soon as the condition is controlled.
II. Nutritional support: regulation of metabolism and support for rehabilitation
Moderate Crohn patients are often associated with malnutrition and sound nutritional support is essential. Intestine nutrient formulations, which are fully balanced in their nutritional composition, both meet the patient ‘ s physical needs and reduce the intestinal burden and promote intestinal mucous membrane restoration. Intestine nutritional support may be considered for those who are unable to withstand intestinal nutrition or who are unable to meet their nutritional needs in cases of intestinal narrowness, inaccessibility, etc. At the same time, micronutrients such as vitamins and minerals are replenished and nutritional deficiencies are corrected according to the patient ‘ s circumstances.
III. Surgery: Strict control and precision
The procedure is not the preferred treatment for the moderately serious Cron disease, but it is necessary to consider certain complications. For example, where intestinal infarction results in intestinal infarction and is ineffective through internal treatment, a narrow form or intestinal ectoplasm can be performed; where intestinal fistula is formed and it is difficult to heal with conservative treatment, it is required to perform an operation to repair or remove a pathological intestinal transformation. However, the re-emergence of Cron ‘ s disease and the high rate of post-surgery re-emergence have necessitated the continuation of after-surgery medication to prevent recurrence.
Psychological intervention: physical and psychological homogeneity, comprehensive care
People with chronic and repeated cases of moderately severe Crohn are prone to psychological problems such as anxiety and depression, which in turn affect the treatment of the disease and the quality of life of the patients. Psychological interventions help patients to understand the disease correctly, build therapeutic confidence and relieve psychological stress. Psychological counselling, cognitive behaviour therapy and, where necessary, combined anti-anger and depressive medication can be used to achieve physical and psychological homogeneity.
In any case, the treatment of the moderately serious Cron disease is a long, systematic and individualized process. Clinicians need to assess in a comprehensive manner the multiple factors of patient activity, intestinal variability, nutritional status, mental state, and efficacy and safety of medication, and to develop treatments that are best suited to the patient, and to monitor them closely and adapt them in a timely manner in order to achieve the best treatments and help the patient to improve his/her quality of life and return to normal life.
